ZDHHC5

Across TCGA pan-cancer cohorts, ZDHHC5 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ZDHHC5 data layer compared with 24 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ZDHHC5 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ZDHHC5 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

HNSC, ACC, and BLCA are the cancer types where ZDHHC5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.059	0.751	<.001	48	view →
ACC	DFS	Median	All	0.046	0.753	<.001	36	view →
BLCA	OS	Median	III,IV	0.051	0.684	<.001	21	view →
UCEC	DFS	Median	All	0.977	0.825	.006	18	view →
ESCA	OS	Median	III,IV	0.117	0.574	.001	12	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ZDHHC5–HNSC (OS)

Open the HNSC breakdown →